Fig. 5.

Change in (A) mTSS, (B) joint-space narrowing, (C) erosion score and (D) percentage of non-progressors

Analyses among non-switchers in the SELECT-EARLY and SELECT COMPARE (as-observed analysis). SELECT-EARLY at 6 months: MTX, n = 232; upadacitinib 15 mg, n = 263; upadacitinib 30 mg, n = 266; and at 1 year: MTX, n = 215; upadacitinib 15 mg, n = 249; upadacitinib 30 mg, n = 255. SELECT-COMPARE at 6 months: upadacitinib 15 mg, n = 348; adalimumab 40 mg, n = 136; and at 1 year: upadacitinib 15 mg, n = 342; adalimumab 40 mg, n = 132. Non-switchers were patients who remained on randomized therapy. eow: every other week; ES: erosion score; JSN: joint-space narrowing score; PBO: placebo; UPA: upadacitinib.